Race, ethnicity help determine which controllable risk factors for dementia have biggest impacts
By
Kristen Fischer
Jan 18, 2024
Controllable risk factors that factor into Alzheimer’s or dementia cases play varying roles based on someone’s race and ethnicity, a new study shows.
FDA approves new drug Leqembi to treat early Alzheimer’s disease
By
Alicia Lasek
Jan 09, 2023
The newly approved drug Leqembi (lecanemab) may slow progression of cognitive decline due to Alzheimer’s disease, trial data show. CMS says it may rethink Medicare coverage of drugs in Leqembi’s...
FDA approves first drug to slow Alzheimer’s in controversial decision
By
Alicia Lasek
Jun 07, 2021
The evidence convincingly shows that aducanumab (Aduhelm) removes beta amyloid — a hallmark of Alzheimer’s — from the brain, slowing the disease’s progression and giving patients and families much-needed...